title: Novel fluoroimmunoassay for ovarian cancer biomarker CA-125.
abstract: Cancer antigen 125 (CA-125) is a glycoprotein biomarker that denotes the presence of ovarian and reproductive cancers in women, with serum concentrations of CA-125 greater than 35 U/ml considered indicative of potential malignancies. A fluorescent immunoassay recently developed in our laboratory employing the ALYGNSA antibody-orientation system has been used to measure CA-125 levels. This system displayed significantly increased sensitivity with a detection limit of 1.5 U/ml compared to that of a commercial CA-125 enzyme-linked immunosorbent assay (15 U/ml) This tenfold lower level of detection of the ALYGNSA CA-125 assay should permit better identification and monitoring of ovarian cancer.
authors.affiliation: Biochemistry Program, Department of Chemistry, College of Arts and Sciences, University of Massachusetts, Lowell, MA, 01854, USA.
authors.forename: Davin
authors.initials: D
authors.lastname: Sok
authors.forename: Lisa-Jo A
authors.initials: LJ
authors.lastname: Clarizia
authors.forename: Leslie R
authors.initials: LR
authors.lastname: Farris
authors.forename: Melisenda J
authors.initials: MJ
authors.lastname: McDonald
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D018269:Carcinoma, Endometrioid / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D005260:Female; D015200:Fluoroimmunoassay; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D012680:Sensitivity and Specificity